Thailand
· Delayed Price · Currency is THB WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of THB 578.60 billion. The enterprise value is 547.03 billion.
| Market Cap | 578.60B |
| Enterprise Value | 547.03B |
Important Dates
The last earnings date was Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.22% |
| Shares Change (QoQ) | -0.48% |
| Owned by Insiders (%) | 1.29% |
| Owned by Institutions (%) | 37.42% |
| Float | 3.73B |
Valuation Ratios
The trailing PE ratio is 26.14 and the forward PE ratio is 19.12.
| PE Ratio | 26.14 |
| Forward PE | 19.12 |
| PS Ratio | 5.89 |
| PB Ratio | 2.42 |
| P/TBV Ratio | 2.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 24.72 |
| EV / Sales | 5.44 |
| EV / EBITDA | 14.98 |
| EV / EBIT | 17.82 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.39 |
| Quick Ratio | 2.96 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.39 |
| Debt / FCF | n/a |
| Interest Coverage | 46.46 |
Financial Efficiency
Return on equity (ROE) is 11.64% and return on invested capital (ROIC) is 12.99%.
| Return on Equity (ROE) | 11.64% |
| Return on Assets (ROA) | 6.88% |
| Return on Invested Capital (ROIC) | 12.99% |
| Return on Capital Employed (ROCE) | 12.00% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.41M |
| Profits Per Employee | 1.67M |
| Employee Count | 13,252 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 8.11 |
Taxes
In the past 12 months, WuXi Biologics has paid 6.87 billion in taxes.
| Income Tax | 6.87B |
| Effective Tax Rate | 21.00% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.70 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.73 |
| Average Volume (20 Days) | 112,199 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of THB 98.25 billion and earned 22.13 billion in profits. Earnings per share was 5.23.
| Revenue | 98.25B |
| Gross Profit | 45.17B |
| Operating Income | 29.97B |
| Pretax Income | 32.72B |
| Net Income | 22.13B |
| EBITDA | 35.66B |
| EBIT | 29.97B |
| Earnings Per Share (EPS) | 5.23 |
Balance Sheet
The company has 70.94 billion in cash and 14.00 billion in debt, giving a net cash position of 56.94 billion.
| Cash & Cash Equivalents | 70.94B |
| Total Debt | 14.00B |
| Net Cash | 56.94B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 239.15B |
| Book Value Per Share | 51.54 |
| Working Capital | 89.40B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 6.01B |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 45.98%, with operating and profit margins of 30.50% and 22.53%.
| Gross Margin | 45.98% |
| Operating Margin | 30.50% |
| Pretax Margin | 33.30% |
| Profit Margin | 22.53% |
| EBITDA Margin | 36.30% |
| EBIT Margin | 30.50% |
| FCF Margin | n/a |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.22% |
| Shareholder Yield | 1.22% |
| Earnings Yield | 3.82% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |